Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Advanced Hepatocellular Carcinoma
NCT02528643Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of enzalutamide in hepatocellular carcinoma (HCC), sponsored by Astellas Pharma. Started Nov 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02528643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528643.